European digital well being teaching firm, Liva Healthcare and international biotechnology organisation, Amgen, have introduced a partnership to make cardiac rehabilitation accessible to sufferers following a coronary heart assault.
The collaboration will allow the businesses to develop Rehab+, a digital tele-rehabilitation resolution that permits sufferers to evaluate their way of life post-heart assault.
The new platform is a part of OPTIMISE, an Amgen-led cardiovascular programme which goals to rework affected person care and display enchancment in outcomes by a spread of initiatives which help sufferers at excessive threat of heart problems.
To develop Rehab+, Amgen additionally partnered with rehabilitation hospitals in Spain, together with La Paz in Madrid, Vall d’Hebron in Barcelona, Virgen de la Victoria in Malaga and Zuyderland within the Netherlands.
Rehab+ is endorsed by the Spanish Society of Cardiology (SEC), Netherlands Society of Cardiology (NVVC) and Foro Español de Pacientes (Spanish Patients Forum).
Amgen Europe and Amgen Spain will likely be programme leaders while Liva Healthcare will present the expertise and the affected person app.
WHY IT MATTERS
With a concentrate on selling self-care, Rehab+ helps sufferers for over one 12 months, serving to them to take management of their very own restoration therapy plan after experiencing a coronary heart assault.
Through the platform, customers are in a position to set private aims to scale back their cardiac threat, and set up way of life adjustments accordingly. Rehab+ goals to equip sufferers to remain engaged with their very own well being in real-time and to handle their cardiac threat elements as a persistent situation to forestall a subsequent coronary heart assault.
Through the app, sufferers will obtain help from knowledgeable coach and obtain academic content material based mostly on their private wants.
The European Institute of Innovation and Technology (EIT) Health just lately introduced that Rehab+ gained the Education Award. This will allow the app to be launched in 4 rehabilitation centres throughout Spain and the Netherlands and evaluated by Maastricht University. Based on the scientific analysis, additional uptake of Rehab+ in extra nations will likely be mentioned.
THE LARGER CONTEXT
Earlier this 12 months, Liva Healthcare raised €24.5 million in a Series B round to drive European management in digital persistent illness prevention and administration.
Meanwhile, the EU has approved an AI technology that may establish individuals prone to a deadly coronary heart assault, years earlier than it occurs. The CaRi-Heart expertise utilises coronary CT angiogram (CTTA) scans already carried out in medical follow.
ON THE RECORD
André Sode, CEO of Liva Healthcare stated: “Amgen is addressing a major hole in cardiac restoration. We are delighted to companion with Amgen, and a strong collective of purpose-driven organisations, to assist enhance the lives of people that have had a coronary heart assault.
“By combining our technology and the expertise of Amgen and the consortium of partners, we can make cardiac rehabilitation easily accessible to more people, empowering them to stay engaged with their own health and, ultimately, reduce their risk of a next heart attack.”
Roman Stampfli, vice chairman advertising and innovation at Amgen stated: “Only a 3rd of the a million individuals who have a coronary heart assault every year in Europe have entry to cardiac rehabilitation to scale back their threat of a second coronary heart assault.
“This partnership is part of our commitment to make cardiac rehabilitation accessible to more patients in the immediate aftermath of a heart attack. By working with Liva Healthcare and this consortium of EU partners, we can co-create an innovative digital tele-rehab solution that helps people establish long-lasting lifestyle changes.”